Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) Operating Margin (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Operating Margin data on record, last reported at 1755.52% in Q4 2025.

  • For Q4 2025, Operating Margin fell 67339.0% year-over-year to 1755.52%; the TTM value through Dec 2025 reached 975.91%, down 21777.0%, while the annual FY2025 figure was 975.91%, 21773.0% down from the prior year.
  • Operating Margin reached 1755.52% in Q4 2025 per ACRS's latest filing, down from 519.82% in the prior quarter.
  • Across five years, Operating Margin topped out at 23.03% in Q4 2023 and bottomed at 1755.52% in Q4 2025.
  • Average Operating Margin over 5 years is 944.08%, with a median of 1059.02% recorded in 2024.
  • The widest YoY moves for Operating Margin: up 123750bps in 2024, down -105910bps in 2024.
  • A 5-year view of Operating Margin shows it stood at 1525.18% in 2021, then surged by 75bps to 375.07% in 2022, then surged by 94bps to 23.03% in 2023, then plummeted by -4598bps to 1082.13% in 2024, then tumbled by -62bps to 1755.52% in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Margin were 1755.52% in Q4 2025, 519.82% in Q3 2025, and 1035.9% in Q2 2025.